Waters Corporation Trading Update – 22 October 2026
Waters Corporation (ticker WAT) closed the trading session at USD 454.8 per share, representing a 3.31 % increase over the previous close. The share price was recorded at 06:18 PM Central Europe on Thursday, 22 October 2026.
Market overview
- Shares outstanding: 98.3 million
- Market capitalization: USD 43.5 billion
- Average daily volume (last 24 h): USD 435.7 million
- 52‑week high: USD 459.63 (21 October 2026)
- 52‑week low: USD 282.77 (13 March 2026)
- 200‑day simple moving average: USD 367.12
- Year‑to‑date performance: 7.45 % up since the end of the previous month
Waters is listed on the New York Stock Exchange and has been a public company since 1995. The firm specializes in high‑performance liquid chromatography (HPLC) and related analytical technologies, serving pharmaceutical, chemical, and environmental testing sectors. For additional information, visit www.waters.com .
Related Stock Performance (Last 24 Hours)
| Company | Ticker | Price change | Current price (USD) | Market cap (USD bn) | P/E ratio |
|---|---|---|---|---|---|
| Humana | HUM | –0.46 % | 424.82 | 51.3 | 40.53 |
| Entergy | ETR | +0.87 % | 107.24 | 50.7 | 26.96 |
| Autodesk | ADSK | –0.30 % | 253.95 | 51.3 | 31.64 |
| Veeva | VEEV | +0.59 % | 322.33 | 51.6 | 51.67 |
| Edwards Lifesciences | EW | +0.12 % | 89.62 | 50.9 | 52.48 |
Key corporate developments
Entergy (ETR) announced a strategic shift toward automation and data‑driven operations. The company is integrating robotics, sensor technologies, and real‑time monitoring tools to improve service reliability and reduce manual intervention. Entergy is exploring partnerships with suppliers of precision sensing and control solutions while maintaining a focus on secure and reliable infrastructure.
Veeva (VEEV) completed a series of corporate actions following its 15th Board of Directors meeting on 8 October 2026. The company will rename itself VEEVA RICO PUBLIC COMPANY LIMITED and update its logo, seal, and registered office address. A capital restructuring plan includes the cancellation of unissued shares, issuance of warrants (META‑W8), and allocation of shares to convert existing convertible debentures. Additionally, Veeva plans a land acquisition in Rayong Province for real‑estate development, with the purchase price matching the appraised market value.
Edwards Lifesciences (EW) received U.S. Food and Drug Administration approval for the PASCAL Precision System for transcatheter tricuspid valve repair, expanding its minimally invasive portfolio. The FDA also approved the PASCAL Ace with Capture Clarity system for mitral valve procedures. Edwards will present one‑year trial results at an upcoming scientific meeting, emphasizing its focus on advancing valve‑replacement technology for high‑risk patients.
These updates provide context for Waters’ recent performance and highlight the broader corporate actions and regulatory developments affecting peer companies in the sector.
